Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80010.010.2122%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Seres Therapeutics Inc

MCRBNASDAQ
Trade with Public
Trade with Public
$5.72
0.081.42%
At close: Sep 4, 5:00 PM EST
$5.36
-0.36-6.29%
After Hours: Sep 2, 9:25 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Seres Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Seres Therapeutics (MCRB).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

2Buy
1Hold
2Sell
Consensus RatingBuy# Analysts5Avg. Consensus PT$10Upside to Avg. PT+90.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 23, 2026HC Wainwright & Co.Matthew KellerInitiateBuy$12
Mar 13, 2026Canaccord GenuityJohn NewmanMaintainedBuy$22
More with Benzinga EdgeGet Access

Analyst Ratings News

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Avi Kapoor

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

PRO
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price target from $1.25 to $6.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved